Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
RADIATION: Radiotherapy
Overall survival in PET/CT non-responders, The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study., 2 years|Overall survival in ITT population, The time between the start of the study treatment (Day 1) and death from any cause or last follow-up for patients alive at the end of the study., 2 years
Local control rate, The time between the start of the study treatment (Day 1) and local reccurence (included the primary tumor and regional lymph node failure), 2 years|Progression-free survival, (defined as the time between Day 1 and the first event of local failure, metastatic recurrence, progression or death), 2 years|Overall survival in PET/CT responders, Overall survival in patients who have SUV â‰¤ 4 in PET/CT analysis in 25-28 radiotherapy fractions., 2 years|Questionnaire EORTC-QLQ-C30, A quality of life score is obtained according to the answers to the questionnaires., 2 years|Questionnaire EORTC-QLQ-OES18, A quality of life score is obtained according to the answers to the questionnaires., 2 years
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.